NCT02112045 · REGISTRY CONDITION SEARCH

A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: TERMINATED
Registry last update: 2019-11-26

This randomized phase II trial compares how well adding XMO2 Filgrastim (Granix) to melphalan before a stem cell transplant works in treating patients with multiple myeloma. Chemotherapy drugs, such as melphalan, are given to prepare the bone marrow for the stem cell transplant. Giving colony-stimulating factors, such as XMO2 Filgrastim (Granix), may help multiple myeloma cells move from the patient's bone marrow to the blood where they may be more sensitive to treatment with melphalan. It is not yet known whether adding XMO2 Filgrastim (Granix) to melphalan before a stem cell transplant will work better than melphalan alone in treating multiple myeloma

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants With Complete Response or Stringent Complete Response

→

outcome · POSTED

Number of Participants With Adverse Events

→

outcome · POSTED

Number of Participants With Overall Response

→

outcome · POSTED

Overall Survival as Measured by Number of Participants Alive at Last Follow-up

→

outcome · POSTED

Progression-free Survival as Measured by Number of Participants Without Disease Progression at Last Follow-up

→

outcome · POSTED

Number of Participants With Neutrophil Engraftment

→

outcome · POSTED

Number of Participants With Platelet Engraftment

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Symptomatic multiple myeloma requiring treatment * Received at least two cycles of any regimen as initial systemic therapy for multiple myeloma and are within 2-12 months of the first dose of initial therapy * At least 18 years of age * Adequate autologous stem cell collection, defined as an unmanipulated, cryopreserved, peripheral blood stem cell collection containing at least 2 × 10\^6 CD34+ cells/kg based on patient body weight. * Adequate organ function as measured by: * Cardiac function: Left ventricular ejection fraction at rest ≥40% * Hepatic function: Bilirubin ≤2 × ULN and aspartate amino transferase/alanine amino transferase (AST/ALT) ≤3 × ULN * Renal function: Creatinine clearance ≥40 mL/minute (measured or calculated/estimated) * Pulmonary function: Carbon monoxide diffusing capacity (DLCO; corrected for hemoglobin \[Hgb\]), forced expiratory volume in 1 second (FEV1), forced expiratory vital capacity (FVC) ≥50% of predicted value * Oxygen saturation ≥92% on room air * Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2. * Able to understand and willing to sign an IRB-approved written informed consent document Exclusion Criteria: * Evidence of multiple myeloma disease progression (as defined by IMWG) any time prior to ASCT * Prior stem cell transplant (autologous or allogeneic) * Smoldering MM not requiring therapy * Plasma cell leukemia * Systemic amyloid light chain amyloidosis * Active bacterial, viral, or fungal infection * Seropositive for human immunodeficiency virus (HIV) * Known, active hepatitis A, B, or C Infection * Pregnant or breastfeeding. * Receiving other concurrent anticancer therapy (including chemotherapy, radiation, hormonal treatment, or immunotherapy, but excluding corticosteroids) within 7 days prior to the ASCT or planning to receive any of these treatments prior to the last study visit on Day +100. * Hypersensitive or intolerant to any component of the study drug(s) formulation * Receiving growth factors (filgrastim, XM02-filgrastim, peg-filgrastim, plerixafor, etc) or undergoing apheresis \< 14 days prior to the start of treatment on protocol (Day -7).
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Granix on Day -7 through Day -2. HDM intravenously (IV) on Day -2. Autologous stem cell transplantation on Day 0
intervention Names
Drug: Granix
Drug: High dose melphalan (HDR)
Procedure: Autologous Stem Cell Transplant (ASCT)
label
Experimental: Granix and high dose melphalan (HDM)
type
EXPERIMENTAL
description
HDM intravenously (IV) on Day -2. Autologous stem cell transplantation on Day 0.
intervention Names
Drug: High dose melphalan (HDR)
Procedure: Autologous Stem Cell Transplant (ASCT)
label
Control: High dose melphalan (HDM)
type
ACTIVE_COMPARATOR

interventions

arm Group Labels
Experimental: Granix and high dose melphalan (HDM)
name
Granix
other Names
XM02 filgrastim
type
DRUG
arm Group Labels
Control: High dose melphalan (HDM)
Experimental: Granix and high dose melphalan (HDM)
name
High dose melphalan (HDR)
other Names
Alkeran® Tablets
Phenylalanine mustard
type
DRUG
arm Group Labels
Control: High dose melphalan (HDM)
Experimental: Granix and high dose melphalan (HDM)
name
Autologous Stem Cell Transplant (ASCT)
type
PROCEDURE

Study design

allocation

RANDOMIZED

intervention Model

PARALLEL

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 90
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Complete response (CR) requires all of the following: * Disappearance of monoclonal protein by both protein electrophoresis and immunofixation studies from the blood and urine * \<5% plasma cells in the bone marrow * Disappearance of soft tissue plasmacytomas Stringent complete response (sCR) requires all of the following: * CR as defined above * Normal free light chain ratio * Absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence
measure
Number of Participants With Complete Response or Stringent Complete Response
time Frame
Day +100

secondary Outcomes

description
-Assessed by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
measure
Number of Participants With Adverse Events
time Frame
Up through Day 30
description
Overall response rate=CR+sCR+VGPR+PR Complete response (CR), disappearance of monoclonal protein from the blood \& urine and \<5% plasma cells in bone marrow \&disappearance of soft tissue plasmacytomas Stringent complete response (sCR), CR \& normal free light chain ratio \& absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence Very good partial response (VGPR), serum and urine monoclonal protein detectable by immunofixation but not on electrophoresis OR \> 90% reduction in serum monoclonal protein with urine monoclonal protein \< 100 mg per 24 hours and if present, \> 50% reduction in the size of soft tissue plasmacytomas Partial response (PR), \> 50% reduction in the level of the serum monoclonal protein \& reduction in urine monoclonal protein \& \> 50% reduction in the size of soft tissue plasmacytomas \& if serum and urine monoclonal protein are unmeasurable and serum free light chain is unmeasurable, a \> 50% reduction in plasma cells is required
measure
Number of Participants With Overall Response
time Frame
Up to 2 years
description
OS is defined as the duration from the time of transplant Day 0 to death or last follow-up.
measure
Overall Survival as Measured by Number of Participants Alive at Last Follow-up
time Frame
Up to 2 years
description
PFS is defined as the duration from time of transplant Day 0 to time of first progression/clinical relapse, death, or the date the patient was last known to be in remission
measure
Progression-free Survival as Measured by Number of Participants Without Disease Progression at Last Follow-up
time Frame
Up to 2 years
description
Neutrophil engraftment is defined as ANC ≥ 0.5 × 10\^9/L × 3 consecutive daily assessments. The first of 3 consecutive days for which ANC ≥ 0.5 × 109/L will be recorded as the date of neutrophil engraftment. Time to neutrophil engraftment will be calculated as the time from the date of the ASCT to the date of neutrophil engraftment.
measure
Number of Participants With Neutrophil Engraftment
time Frame
Up to Day 30
description
Platelet engraftment is defined as an untransfused platelet measurement \>20,000/mm3 × 3 consecutive daily assessments. The first of 3 consecutive days for which the untransfused platelet measurement is \>20,000/mm3 will be recorded as the date of platelet engraftment. Time to platelet engraftment will be calculated as the time from receiving the date of ASCT to the date of platelet engraftment. Untransfused is defined as no transfusions within 7 days.
measure
Number of Participants With Platelet Engraftment
time Frame
Up to Day 100

Full study description

brief Summary: This randomized phase II trial compares how well adding XMO2 Filgrastim (Granix) to melphalan before a stem cell transplant works in treating patients with multiple myeloma. Chemotherapy drugs, such as melphalan, are given to prepare the bone marrow for the stem cell transplant. Giving colony-stimulating factors, such as XMO2 Filgrastim (Granix), may help multiple myeloma cells move from the patient's bone marrow to the blood where they may be more sensitive to treatment with melphalan. It is not yet known whether adding XMO2 Filgrastim (Granix) to melphalan before a stem cell transplant will work better than melphalan alone in treating multiple myeloma

Source references